At the most basic level, the goal of healthcare is to prevent disease or injury, or to relieve it when it is present. In doing so, we have traditionally measured our success through treatment outcomes, such as the eradication of an infection, the restoration of walking ability, or the prolongation of life. But the impact of an intervention occurs in the context of a patient's overall health condition and existing comorbidities. Thus, assessing changes in health-related quality of life (HRQoL) allows us to measure a more comprehensive outcome that reflects the patient as a whole.
Initial HRQoL measures were simple assessments of physical measures by an external rater, such as the ability of a person to perform activities of daily living. The modern concept of HRQoL recognizes that patients perceive their level of health in the context of individual expectations, chronicity of disease, family support, and other situational factors. Not surprisingly, HRQoL ratings by patients and their physicians often differ. Thus, most currently used HRQoL instruments are now questionnaires that are completed by the patients themselves. These tools are integral in quantifying patient-centered outcomes in research, evaluating patients over time, and medical decision-making. 1, 2 Beyond its traditional use as an outcome measure, HRQoL is being increasingly used as a predictor of outcomes, especially survival. 3 Much of this work has been in patients with coronary heart disease (CHD) [3] [4] [5] and congestive heart failure (CHF), 6 where lower HRQoL was significantly associated with higher mortality. The current work by Issa et al. 7 represents the first study of its kind in patients with peripheral arterial disease (PAD). Their analysis comes from a prospective observational cohort study of Dutch patients who have undergone open or endovascular surgical procedures for PAD and survived at least 1 year. The EQ-5D survey was administered to these patients, and mortality was assessed at 3 years after surgery.
EQ-5D was developed by the European Quality of Life Group (EuroQol) as a non-disease-specific, validated instrument for describing and valuing HRQoL. 8 It consists of a descriptive system comprised of five dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. It is designed to be cognitively simple, quick to complete, and easily self-administered. Currently, EQ-5D is available in 81 languages with more awaiting approval by the EuroQol Translation Committee. Its use in cardiovascular patients is has been validated 9-11 and well established, [12] [13] [14] and thus makes it a suitable instrument for the current study. EQ-5D also contains a visual analog scale (VAS) component that records the subject's self-rated health status on a vertical graduated (0-100) scale. VAS serves as the utility measure that allows conversion of the results for use in decision and cost-effectiveness analysis.
Issa et al. found that for the 503 patients who completed the survey, low HRQoL was significantly associated with higher mortality at 3 years after surgery (2 years after survey completion) (hazard ratio = 5.4, 95% CI 2.3-12.5). The observed mortality rates (11% for those who completed surveys, and 13% for those who did not) are similar to other published mortality rates for the PAD population, 15 especially considering their patients were a subset that required intervention. 16 Their findings that HRQoL was associated with mortality independent of expected risk factors (older age, chronic obstructive pulmonary disease, CHF, renal failure, and prior arrhythmias) supports the notion that HRQoL be used in clinical practice to guide treatment decisions and improve secondary prevention in PAD patients.
The mechanism for the observed association of low HRQoL and mortality is not clear, however. 4 HRQoL may be a proxy for the uncharacterized patient factors that are not captured in mortality models. For example, specific components of HRQoL may be related to mortality through depression or personality type. Among patients with symptomatic PAD, a finding of type D personality, which refers to the tendency to experience negative emotions and to inhibit selfexpression in social interaction, was independently related to all-cause mortality after adjusting for age, ankle-brachial index, diabetes, pulmonary disease, and renal disease. 17 Poor HRQoL may also be a proxy for other unmeasured confounders such as disease severity, co-morbid depression, socioeconomic status, and decreased access to or utilization of health care services (Henry and Nguyen, unpublished).
As Issa et al. have noted, it is also not clear whether attempts to improve HRQoL would also improve survival. While there is a natural association between successful treatment and improved HRQoL in most disease processes, the magnitude of such improvements may be diluted by comorbidities not addressed by the treatment in question 18 and the severity of the treatment process itself. 2, 19 Indeed, others have shown that the initial improvements in HRQoL after treatment may not be sustained in long-term follow-up of patients with comorbidities, such as diabetes. 20 All clinical research involving survey instruments can be affected by biases resulting from incomplete surveys. Issa et al. compared survey responders versus non-responders and found similar demographic characteristics between the two groups with the exception that non-responders were more likely to be women and have CHF. Since only patients who were alive at 1 year after surgery were offered surveys, their results may also be over-estimating the level of HRQoL in this population, because patients who did not survive to 1 year (and hence would have zero HRQoL) were not assessed. It would have been also interesting to administer surveys before surgery to capture the immediate effect of treatment on HRQoL and better understand its longevity.
These limitations withstanding, this manuscript represents an important contribution to the growing recognition that HRQoL is both an outcome measure and a process measure. Modern healthcare is not just concerned about improving survival, but also optimizing the quality of life during those years. To do so, we need to incorporate measures of HRQoL in our clinical research designs, if not in daily clinical practice, whenever feasible. In doing so, we can analyze composite outcomes relevant to the patient's perspective, and identify those who are in most need of attention or have the most health quality to gain.
